BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38028081)

  • 1. Erythema nodosum following treatment with dasatinib plus chemotherapy in a patient with myeloid blast phase of chronic myeloid leukemia.
    Kassem N; Alshurafa A; Elsabah H; El Omri H
    Clin Case Rep; 2023 Nov; 11(11):e8223. PubMed ID: 38028081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
    Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
    Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.
    Abaza Y; Kantarjian H; Alwash Y; Borthakur G; Champlin R; Kadia T; Garcia-Manero G; Daver N; Ravandi F; Verstovsek S; Burger J; Estrov Z; Ohanian M; Lim M; Pemmaraju N; Jabbour E; Cortes J
    Am J Hematol; 2020 Nov; 95(11):1288-1295. PubMed ID: 32681739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
    Saglio G; Hochhaus A; Goh YT; Masszi T; Pasquini R; Maloisel F; Erben P; Cortes J; Paquette R; Bradley-Garelik MB; Zhu C; Dombret H
    Cancer; 2010 Aug; 116(16):3852-61. PubMed ID: 20564086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Keam SJ
    BioDrugs; 2008; 22(1):59-69. PubMed ID: 18215092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
    Rogers G; Hoyle M; Thompson Coon J; Moxham T; Liu Z; Pitt M; Stein K
    Health Technol Assess; 2012; 16(22):1-410. PubMed ID: 22551803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    McCormack PL; Keam SJ
    BioDrugs; 2012 Feb; 26(1):61-4. PubMed ID: 22233429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
    Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
    Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
    Cortes J; Kim DW; Raffoux E; Martinelli G; Ritchie E; Roy L; Coutre S; Corm S; Hamerschlak N; Tang JL; Hochhaus A; Khoury HJ; Brümmendorf TH; Michallet M; Rege-Cambrin G; Gambacorti-Passerini C; Radich JP; Ernst T; Zhu C; Van Tornout JM; Talpaz M
    Leukemia; 2008 Dec; 22(12):2176-83. PubMed ID: 18754032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report.
    Maat Z; Mushtaq K; Yassin MA
    Case Rep Oncol; 2021; 14(3):1441-1446. PubMed ID: 34899234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the combination of SSKI and topical heparin in a case of erythema nodosum migrans.
    Sehrawat M; Dixit N; Sardana K; Malhotra P
    Dermatol Ther; 2018 Jul; 31(4):e12610. PubMed ID: 29644775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.
    Morita K; Kantarjian HM; Sasaki K; Issa GC; Jain N; Konopleva M; Short NJ; Takahashi K; DiNardo CD; Kadia TM; Garcia-Manero G; Daver N; Montalban Bravo G; Cortes JE; Ravandi F; Jabbour E
    Cancer; 2021 Aug; 127(15):2641-2647. PubMed ID: 33823073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of etanercept in management of tyrosine kinase-inhibitor-induced erythema nodosum.
    Alia E; Varma A; Brody J; Keyzner A; Singh R; Levitt J
    JAAD Case Rep; 2020 Jun; 6(6):567-568. PubMed ID: 32509950
    [No Abstract]   [Full Text] [Related]  

  • 15. Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia.
    Qing X; Qing A; Ji P; French SW; Mason H
    Exp Mol Pathol; 2018 Apr; 104(2):130-133. PubMed ID: 29501750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute myeloid leukemia presenting as erythema nodosum: A case report.
    Xu X; Liang G; Duan M; Zhang L
    Medicine (Baltimore); 2017 Nov; 96(47):e8666. PubMed ID: 29381943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sudden blast phase in chronic myeloid leukemia developed during nilotinib therapy after major molecular response was achieved.
    Okada Y; Sato K; Kobayashi S; Nagao S; Takano K; Teramoto M; Tachi N; Kawamura T; Horiuchi T; Kato S; Saga R; Maekawa T; Yamamura T; Watanabe J; Kobayashi A; Kimura F
    Int J Hematol; 2018 Apr; 107(4):495-497. PubMed ID: 29032513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.
    Strati P; Kantarjian H; Thomas D; O'Brien S; Konoplev S; Jorgensen JL; Luthra R; Abruzzo L; Jabbour E; Quintas-Cardama A; Borthakur G; Faderl S; Ravandi F; Cortes J
    Cancer; 2014 Feb; 120(3):373-80. PubMed ID: 24151050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    McCormack PL; Keam SJ
    Drugs; 2011 Sep; 71(13):1771-95. PubMed ID: 21902298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.